ASP2409, A Next‐Generation CTLA4‐Ig, Versus Belatacept in Renal Allograft Survival in Cynomolgus Monkeys

Belatacept is the first costimulatory blockade agent approved for maintenance immunosuppression in kidney transplant recipients. Clinical results have indicated that belatacept is associated with superior renal function and improved metabolic profile; however, higher incidence of acute rejection and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of transplantation 2017-03, Vol.17 (3), p.635-645
Hauptverfasser:	Song, L., Ma, A., Dun, H., Hu, Y., Fujii, Y., Kinugasa, F., Oshima, S., Higashi, Y., Daloze, P., Chen, H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Abatacept - pharmacology animal models: nonhuman primate Animals B7-2 Antigen - immunology basic (laboratory) research/science Drug Therapy, Combination fusion proteins and monoclonal antibodies: costimulation molecule specific Glomerular Filtration Rate Graft Rejection - drug therapy Graft Rejection - etiology Graft Survival - drug effects Immunoconjugates - pharmacology immunosuppressant immunosuppression/immune modulation Immunosuppressive Agents - pharmacology Kidney Failure, Chronic - surgery Kidney Function Tests Kidney Transplantation - adverse effects kidney transplantation/nephrology Macaca fascicularis Male pharmacokinetics/pharmacodynamics rejection: acute T-Lymphocytes, Cytotoxic - immunology Tacrolimus - pharmacology Transplantation, Homologous Transplants & implants
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!